ANDA 90941, held by Rising. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 90941 (Bupropion Hydrochloride), held by Rising, was first approved by FDA on May 3, 2010, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 3, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bupropion Hydrochloride150MG · tablet, extended release;oral | Bupropion Hydrochloride | Discontinued |
| Nov 5, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 7, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Apr 16, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 16, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 28, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 28, 2017 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 3, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters